Cilostazol is an antiplatelet aggregation inhibitor drug associated with increased cerebral blood flow and inflammation suppression. This study evaluated administration of cilostazol to prevent cerebral vasospasm following subarachnoid hemorrhage (SAH) in 50 patients treated surgically from December 2004 to November 2006. All patients, excluding those with Hunt and Kosnik grade 5 or who had undergone late surgery, were classified into two groups: 26 patients who received 200 mg/day cilostazol from postoperative day 1 to day 14 and 24 control patients. The frequency and the degree of cerebral vasospasm, occurrence of ischemic lesion, and clinical symptoms due to vasospasm were compared between the two groups. The appearance of severe vasospasm on angiography, persistent symptomatic spasm, and new cerebral infarction due to vasospasm demonstrated by neuroimaging were apparently lower in the cilostazol group than in the control group, suggesting that cilostazol may significantly suppress cerebral vasospasm following SAH.
Introduction
Cerebral vasospasm is the most serious complication of subarachnoid hemorrhage (SAH), and the etiology and pathogenesis remain unclear. Vasospasm can be reduced by intraoperative removal of the clot and postoperative administration of papaverine or fasudil hydrochloride, 9, 23, 25) or by endovascular treatment, which have improved the prognosis for patients with cerebral vasospasm. 9, 25) However, symptomatic vasospasm still occurs in approximately 30% of patients with SAH, and has serious sequelae in 10%. 11) Cilostazol is a selective inhibitor of phosphodiesterase 3 which increases intracellular cyclic adenosine monophosphate content, resulting in inhibition of platelet aggregation and peripheral vasodilation mediated by adenosine diphosphate collagen, epinephrine, and arachidonic acid. 5, 12, 27) Cilostazol effectively suppresses the incidence of cerebral stroke, like other anti-platelet aggregation drugs, but also has a unique stabilization effect on the vascular membrane, 6, 7, 12, 14, 17) which suppresses certain inflammation mechanisms. The inflammatory mechanisms are profoundly related to the processes of cerebral infarction and atherosclerotic change, 22, 30) so cilostazol may also ameliorate the progress of atherosclerosis. Such inflammation processes may also be important in the pathogenesis of cerebral vasospasm. [2] [3] [4] 11, 15, 16, 21) The present preliminary study investigated whether cilostazol affects the incidence of vasospasm.
Patients and Methods
This study included 50 patients with SAH caused by ruptured cerebral aneurysm treated in our hospital between December 2004 and November 2006. Patients with extremely severe SAH of Hunt and Kosnik grade 5 or patients who underwent late surgery were excluded. The 26 patients admitted within the last year were treated with cilostazol 200 mg/day from day 1 after surgery for 2 weeks, and formed the cilostazol group, and the other 24 patients treated during the first year formed the control group. All patients with ruptured aneurysms causing SAH of Hunt and Kosnik grades 1 to 4 may be treated by clipping or coiling within a couple of days of onset. Clipping surgery was the dominant procedure and was performed by the same neurosurgeon, whereas endovascular specialist performed all coiling procedures. Postoperative management was uniform in all patients. The patient or next of kin received explanations of the nature of the agent and the purpose of this study, and written informed consent was obtained for each patient prior to entering the study. This study was approved by the ethics review board at this hospital in accordance with the Helsinki declaration.
Neurological examinations were performed every 4 hours from immediately postoperatively to day 14 in the stroke care unit. If any neurological deterioration was detected, diffusion-weighted magnetic resonance (MR) imaging and MR angiography were performed to identify any new ischemic lesion, and emergent cerebral angiography was performed to detect the presence of cerebral vasospasm. Postoperative management consisted of control of volume and blood pressure, and allowed administration of fasudil hydrochloride 60 mg/day from day 1 to day 14, and low molecular weight dextran 500 ml/day from day 3 to day 14. Urokinase 6000 U was given twice in the cerebrospinal fluid through the cisternal or spinal drainage for 3 days from day 1 after surgery to wash out any clots. Systolic blood pressure was controlled above 110 mmHg and below 190 mmHg, and central venous pressure was maintained above 6 cmH 2 O and below 14 cmH 2 O.
The modified Rankin scale (mRS) was estimated at discharge or 1 month later. Computed tomography (CT) or MR imaging was usually performed every 1 or 2 days after surgery. New lesions not attributable to other causes were interpreted as ischemic lesions caused by cerebral vasospasm, regardless of any association with symptoms. Transcranial Doppler ultrasonography was performed every day from day 2 to measure the blood flow velocities in the bilateral horizontal portions of the middle cerebral artery (MCA) and the anterior cerebral artery (ACA). The critical threshold for sequential mean blood flow velocities was above 180 cm/sec, 50 cm/sec higher than the previous accepted value, so that vasospasm could be close to severe and treatment should be taken into consideration.
Cerebral angiography was periodically performed between days 7 and 9 in patients not showing any clinical deterioration. Emergent cerebral angiography was carried out if postoperative neurological deterioration was caused by vasospasm or if postoperative examinations indicated vasospasm. The findings were classified as described previously 9) : none, mild (less than 50% reduction in vessel diameter), moderate (50% reduction), and severe (more than 50% reduction or diffuse narrowing of vessels). If severe vasospasm or symptomatic vasospasm occurred, 15 to 90 mg fasudil hydrochloride was given intra-arterially at the immediately proximal site of the artery through a micro catheter. If repeated injections of fasudil hydrochloride obtained poor or no response, the horizontal portion of the MCA or ACA was mechanically dilated with a balloon microcatheter. This endovascular treatment was repeated several times if needed.
The temporary or persistent neurological symptoms, critical velocity increase, moderate or severe vasospasm, presence of new lesions, and necessity for endovascular treatment were compared between the cilostazol group and the control group, using the chi-square test.
Results Table 1 shows the clinical characteristics of the patients in the cilostazol and control groups. There were no significant differences in any of these characteristics. 
Cilostazol Efficacy to Vasospasm
Postoperative angiography demonstrated severe vasospasm in 2 of the 26 patients in the cilostazol group versus 7 of the 24 patients in the control group (p º 0.05), and moderate or severe vasospasm in 4 of 26 versus 10 of 24 (p º 0.05), showing that the cilostazol group had significantly less severe angiographical vasospasm (Fig. 1) . Transcranial Doppler ultrasonography showed 6 of the 26 patients in the cilostazol group and 9 of the 24 patients in the control group exceeded the critical velocity threshold, without significant difference.
New temporary symptoms caused by vasospasm occurred in 4 of the 26 patients in the cilostazol group and 3 of the 24 patients in the control group. The transient symptoms in the cilostazol group included aphasia in two patients, right hemiparesis in one, and consciousness disturbances in one during the postoperative course, and all improved within a few days. The transient symptoms in the control group included confusion, aphasia, and right hemiparesis. Persistent symptoms developed in 1 of the 26 patients in the cilostazol group and 6 of the 24 patients in the control group, showing a significant difference (p º 0.01). The persistent symptoms were aphasia in the cilostazol group, and deterioration of disturbed consciousness, aphasia, right hemiparesis, and agnosia in the control group. Therefore, symptomatic vasospasm occurred in 5 of the 26 patients in the cilostazol group and 9 of the 24 patients in the control group, showing a reduction by cilostazol, but not significantly. New lesions caused by vasospasm on CT or MR imaging were de- tected in 3 of the 26 patients in the cilostazol group and 7 of the 24 patients in the control group, showing no significant difference (Fig. 2) . Seven of the 26 patients in the cilostazol group received endovascular treatment for vasospasm, compared with 11 of the 24 patients in the control group. Furthermore, only 2 of the 26 patients in the cilostazol group required two or more endovascular procedures, whereas 6 of the 24 patients in the control group required two or more endovascular procedures. The need for endovascular treatment was apparently less in the cilostazol group, although not statistically significant (Fig. 3) . Table 2 shows the changes in mRS. Improvement of serious cases to mRS 0 and 1 was remarkable in the cilostazol group, compared to the control group. However, 20 of the 26 patients in the cilostazol group and 17 of the 24 patients in the control group achieved mRS 0 or 1 on discharge or 1 month later, with no significant difference.
Discussion
This study indicated that cilostazol may effectively decrease the frequency and the degree of cerebral vasospasm, and improve the outcome after SAH. Various actions of cilostazol may be related to the process as follows: increased nitric oxide (NO) levels derived from endothelial cells, 6, 7, 14) inhibition of vascular smooth muscle proliferation, 26) suppression of adhesion molecule expression on the vascular membrane, 17) and inhibition of platelet-derived growth factor production. 10) These effects can induce vascular dilation and suppression of secondary inflammation processes, 13) resulting in the prevention of ischemia and progression of atherosclerosis. These characteristic actions of cilostazol are different to those of other platelet aggregation inhibitors.
Oxyhemoglobin, which is speculated to be a basic cause in the pathogenesis of cerebral vasospasm, is released in the cerebrospinal fluid after SAH and induces increased diacylglycerol expression in the vascular wall, as well as continuous activation of protein kinase C (PKC), which can excite free radical reactions with cytotoxic effect inside and outside the arterial wall and scavenge NO. 18, 26) In addition, the activity of endothelial NO synthetase decreases, which is physiologically related to vasodilation, so the imbalance between endothelin-mediated vasoconstriction and NO-mediated vasodilation may also be one of the crucial mechanisms. 8, 19, 20, 24) The inflammation process may be further induced by white blood cell attractant and adhesion molecule expression. The other participatory mechanism is thought to be the inflammatory process caused by leukocyte-endothelial cell interactions. [2] [3] [4] 11, 15, 16) Leukocytes and endothelial cells activate one another through adhesion molecules to produce endothelin and reactive oxygen species, and can deplete NO, all of which may cause cerebral vasospasm. Anti-inflammatory agents and selective anti-CD11/CD18 monoclonal antibody are effective for reducing the occurrence of cerebral vasospasm. 2-4,21) Interleukin-6 and several inflammatory cytokines are also involved in vasospasm after SAH. 16) These actions occurring in the inflammatory process may combine with the effects of oxyhemoglobin to result in the potency of vasoconstriction.
The Ca 2＋ -independent vascular smooth muscle constriction theory requires the activation of PKC by increased diacylglycerol expression in the cell membrane, which is important both in the initiation and the continuance of cerebral vasospasm. 1) Cilostazol may affect this process through increased cyclic adenosine monophosphate levels. Recently, Rho/Rho kinase has been demonstrated to be crucial in cerebral vasoconstriction mediated by oxyhemoglobin. 28, 29) Fasudil hydrochloride can directly affect the suppression of vascular contraction by inhibition of myosin light chain phosphatase, and thus decrease the frequency of cerebral vasospasm. 25) Cilostazol has several anti-inflammatory effects as well as the induction of NO, and the relationship to PKC or Rho/Rho kinase provides another route to elucidate this effect further.
This study could not specifically elucidate the contribution of cilostazol to the improvement of the final outcome, although the incidence of vasospasm was decreased. The cilostazol group also apparently contained more serious cases on admission than the control group. However, this study suggests that administration of cilostazol should be investigated for the management of vasospasm after SAH. T. Yoshimoto et al. 
Commentary
Yoshimoto et al. present here a pilot study of the effects of an antiplatelet medication, cilostazol, on the incidence of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Cilostazol is a platelet aggregation inhibitor and arterial smooth muscle dilator, employed commonly in the treatment of peripheral vascular disease. Cilostazol has a well-described mechanism of action; by acting as a phosphodiesterase-3 inhibitor, it increases intracellular cAMP, causing antiplatelet effects and vasodilation. In addition, cilostazol has a unique anti-inflammatory characteristic. It is such inflammatory processes that have been implicated in the development of vasospasm.
The study included 50 patients placed in one of two groups -cilostazol group and the control group. Both groups had similar demographics except for the Hunt and Hess scores, with the cilostazol group containing more grade 4 subarachnoid hemorrhages. Parameters that were studied included outcome (measured by modified Rankin scale), neurological symptoms (transient and permanent), transcranial Doppler velocities, CT/MRI changes, and cerebral angiography for diagnosing the degree of vasospasm (mild, moderate or severe) and endovascular interventions.
The results showed a significant decrease in moderate and severe vasospasm in the cilostazol group. Additionally, the development of new permanent symptoms in the cilostazol cohort was statistically significantly less than the control group (1/26 vs. 6/24). The remainder of results failed to reach statistical significance, but suggested a trend toward less vasospasm seen in the treatment arm of the study.
The study is limited by a small sample size; however, I do believe the results warrant further investigation. Seeing a reduction in vasospasm using a medication, like cilostazol, that has a well described mechanism of action, provides valuable pathophysiologic information about vasospasm. The authors discuss several possible mechanisms by which cilostazol may act -i.e. increasing nitric oxide levels derived from endothelial cells, inhibiting the vascular smooth muscle proliferation, suppressing adhesion molecule expression and inhibiting platelet-derived growth factor production. Additionally, the calcium independent vascular smooth muscle constriction theory that has been implicated in cerebral vasospasm requires acti-
